Behavioral effects of urotensin-II centrally administered in mice

被引:48
作者
Do-Rego, JC
Chatenet, D
Orta, MH
Naudin, B
Le Cudennec, C
Leprince, J
Scalbert, E
Vaudry, H
Costentin, J
机构
[1] CNRS, UFR Med & Pharm, Inst Federat Rech Multidisciplinaires Peptides IF, Lab Neuropsychopharmacol Expt,FRE 2735, F-76183 Rouen, France
[2] Univ Rouen, INSERM U413, IFRMP 23, Lab Neuroendocrinol Cellulaire & Mol, F-76821 Mont St Aignan, France
[3] Inst Rech SERVIER IDRS, F-92150 Suresnes, France
关键词
urotensin-II; mouse; central nervous system; behavioral effects;
D O I
10.1007/s00213-005-0140-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Urotensin-II (U-II) receptors are widely distributed in the central nervous system. Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion. However, the behavioral effects of centrally administered U-II have received little attention. In the present study, we tested the effects of i.c.v. injections of U-II on behavioral, metabolic, and endocrine responses in mice. Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test. Intracerebroventricular injection of U-II also caused an increase in: food intake at doses of 100 and 1,000 ng/mouse, water intake at doses of 100-10,000 ng/ mouse, and horizontal locomotion activity at a dose of 10,000 ng/mouse. Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level. Taken together, the present study demonstrates that the central injection of U-II at doses of 1-10,000 ng/ mouse induces anxiogenic- and depressant-like effects in mouse. These data suggest that U-II may be involved in some aspects of psychiatric disorders.
引用
收藏
页码:103 / 117
页数:15
相关论文
共 70 条
[1]   Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J].
Ames, RS ;
Sarau, HM ;
Chambers, JK ;
Willette, RN ;
Alyar, NV ;
Romanic, AM ;
Louden, CS ;
Foley, JJ ;
Sauermelch, CF ;
Coatney, RW ;
Ao, ZH ;
Disa, J ;
Holmes, SD ;
Stadel, JM ;
Martin, JD ;
Liu, WS ;
Glover, GI ;
Wilson, S ;
McNulty, DE ;
Ellis, CE ;
Elshourbagy, NA ;
Shabon, U ;
Trill, JJ ;
Hay, DWP ;
Ohlstein, EH ;
Bergsma, DJ ;
Douglas, SA .
NATURE, 1999, 401 (6750) :282-286
[2]   The role of corticotropin-releasing factor in depression and anxiety disorders [J].
Arborelius, L ;
Owens, MJ ;
Plotsky, PM ;
Nemeroff, CB .
JOURNAL OF ENDOCRINOLOGY, 1999, 160 (01) :1-12
[3]   DO ANTIDEPRESSANTS STABILIZE MOOD THROUGH ACTIONS ON THE HYPOTHALAMIC-PITUITARY-ADRENOCORTICAL SYSTEM [J].
BARDEN, N ;
REUL, JMHM ;
HOLSBOER, F .
TRENDS IN NEUROSCIENCES, 1995, 18 (01) :6-11
[4]  
Bern H.A., 1985, Recent Progress in Hormone Research, V41, P533
[5]   FURTHER CHARACTERIZATION OF A SIMPLE, AUTOMATED EXPLORATORY MODEL FOR THE ANXIOLYTIC EFFECTS OF BENZODIAZEPINES [J].
BLUMSTEIN, LK ;
CRAWLEY, JN .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1983, 18 (01) :37-40
[6]  
BOISSIER J R, 1962, Therapie, V17, P1225
[7]   A neuroanatomic model for depression [J].
Byrum, CE ;
Ahearn, EP ;
Krishnan, KRR .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1999, 23 (02) :175-193
[8]   Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord [J].
Chartrel, N ;
Leprince, J ;
Dujardin, C ;
Chatenet, D ;
Tollemer, H ;
Baroncini, M ;
Balment, RJ ;
Beauvillain, JC ;
Vaudry, H .
JOURNAL OF NEUROCHEMISTRY, 2004, 91 (01) :110-118
[9]  
Chartrel N, 1996, J COMP NEUROL, V364, P324
[10]   Structure-activity relationships and structural conformation of a novel urotensin II-related peptide [J].
Chatenet, D ;
Dubessy, C ;
Leprince, J ;
Boularan, C ;
Carlier, L ;
Ségalas-Milazzo, I ;
Guilhaudis, L ;
Oulyadi, H ;
Davoust, D ;
Scalbert, E ;
Pfeiffer, B ;
Renard, P ;
Tonon, MC ;
Lihrmann, I ;
Pacaud, P ;
Vaudry, H .
PEPTIDES, 2004, 25 (10) :1819-1830